These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 8728542)

  • 1. Modulation of plus-maze behaviour in mice by the preferential D3-receptor agonist 7-OH-DPAT.
    Rodgers RJ; Johnson NJ; Champion AJ; Mills S
    Pharmacol Biochem Behav; 1996 May; 54(1):79-84. PubMed ID: 8728542
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Behavioural effects of 7-OH-DPAT are solely due to stimulation of dopamine D2 receptors in the shell of the nucleus accumbens; turning behaviour.
    Koshikawa N; Kitamura M; Kobayashi M; Cools AR
    Eur J Pharmacol; 1996 Jul; 308(3):235-41. PubMed ID: 8858293
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dopamine D1 and D2 receptor ligands modulate the behaviour of mice in the elevated plus-maze.
    Rodgers RJ; Nikulina EM; Cole JC
    Pharmacol Biochem Behav; 1994 Dec; 49(4):985-95. PubMed ID: 7886117
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Behavioural effects of 7-OH-DPAT are solely due to stimulation of dopamine D2 receptors in the shell of the nucleus accumbens; jaw movements.
    Koshikawa N; Miwa Y; Adachi K; Kobayashi M; Cools AR
    Eur J Pharmacol; 1996 Jul; 308(3):227-34. PubMed ID: 8858292
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functional correlates of dopamine D3 receptor activation in the rat in vivo and their modulation by the selective antagonist, (+)-S 14297: II. Both D2 and "silent" D3 autoreceptors control synthesis and release in mesolimbic, mesocortical and nigrostriatal pathways.
    Gobert A; Rivet JM; Audinot V; Cistarelli L; Spedding M; Vian J; Peglion JL; Millan MJ
    J Pharmacol Exp Ther; 1995 Nov; 275(2):899-913. PubMed ID: 7473181
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Repeated imipramine treatment enhances the 7-OH-DPAT-induced hyperactivity in rats: the role of dopamine D2 and D3 receptors.
    Rogóz Z; Skuza G
    Pol J Pharmacol; 2001; 53(6):571-6. PubMed ID: 11985330
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lack of discrimination by agonists for D2 and D3 dopamine receptors.
    Burris KD; Pacheco MA; Filtz TM; Kung MP; Kung HF; Molinoff PB
    Neuropsychopharmacology; 1995 Jul; 12(4):335-45. PubMed ID: 7576010
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 7-OH-DPAT effects on latent inhibition: low dose facilitation but high dose blockade: implications for dopamine receptor involvement in attentional processes.
    Chagas-Martinich L; Carey RJ; Carrera MP
    Pharmacol Biochem Behav; 2007 Mar; 86(3):441-8. PubMed ID: 17291574
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dopamine D3 receptor-preferring agonists increase dendrite arborization of mesencephalic dopaminergic neurons via extracellular signal-regulated kinase phosphorylation.
    Collo G; Zanetti S; Missale C; Spano P
    Eur J Neurosci; 2008 Oct; 28(7):1231-40. PubMed ID: 18973551
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antianxiety and behavioral suppressant actions of the novel 5-HT1A receptor agonist, flesinoxan.
    Rodgers RJ; Cole JC; Davies A
    Pharmacol Biochem Behav; 1994 Aug; 48(4):959-63. PubMed ID: 7972301
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The D3 antagonist PNU-99194A potentiates the discriminative cue produced by the D3 agonist 7-OH-DPAT.
    Depoortere R; Perrault G; Sanger DJ
    Pharmacol Biochem Behav; 2000 Jan; 65(1):31-4. PubMed ID: 10638632
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of D2 and D3 receptor-selective ligands in rats trained to discriminate cocaine from saline.
    Garner KJ; Baker LE
    Pharmacol Biochem Behav; 1999 Oct; 64(2):373-8. PubMed ID: 10515316
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ethological evaluation of the effects of acute and chronic buspirone treatment in the murine elevated plus-maze test: comparison with haloperidol.
    Cole JC; Rodgers RJ
    Psychopharmacology (Berl); 1994 Mar; 114(2):288-96. PubMed ID: 7838922
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Agonist and inverse agonist activity at the dopamine D3 receptor measured by guanosine 5'--gamma-thio-triphosphate--35S- binding.
    Malmberg ; Mikaels ; Mohell N
    J Pharmacol Exp Ther; 1998 Apr; 285(1):119-26. PubMed ID: 9536001
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of D3/D2 dopamine receptor agonists and antagonists on prepulse inhibition of acoustic startle in the rat.
    Caine SB; Geyer MA; Swerdlow NR
    Neuropsychopharmacology; 1995 Apr; 12(2):139-45. PubMed ID: 7779242
    [TBL] [Abstract][Full Text] [Related]  

  • 16. S33084, a novel, potent, selective, and competitive antagonist at dopamine D(3)-receptors: II. Functional and behavioral profile compared with GR218,231 and L741,626.
    Millan MJ; Dekeyne A; Rivet JM; Dubuffet T; Lavielle G; Brocco M
    J Pharmacol Exp Ther; 2000 Jun; 293(3):1063-73. PubMed ID: 10869411
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Infralimbic D2 receptor influences on anxiety-like behavior and active memory/attention in CD-1 mice.
    Wall PM; Blanchard RJ; Yang M; Blanchard DC
    Prog Neuropsychopharmacol Biol Psychiatry; 2003 May; 27(3):395-410. PubMed ID: 12691774
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plus-maze retest profile in mice: importance of initial stages of trail 1 and response to post-trail cholinergic receptor blockade.
    Rodgers RJ; Johnson NJ; Cole JC; Dewar CV; Kidd GR; Kimpson PH
    Pharmacol Biochem Behav; 1996 May; 54(1):41-50. PubMed ID: 8728537
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Involvement of the dorsal hippocampal dopamine D2 receptors in histamine-induced anxiogenic-like effects in mice.
    Piri M; Ayazi E; Zarrindast MR
    Neurosci Lett; 2013 Aug; 550():139-44. PubMed ID: 23872092
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anxiolytic- and antidepressant-like effects of 7-OH-DPAT, preferential dopamine D3 receptor agonist, in rats.
    Rogóz Z; Skuza G; Kłlodzińska A
    Pol J Pharmacol; 2004; 56(5):519-26. PubMed ID: 15591639
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.